The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The United States specialty generics market was valued at US$ 21 Billion in 2020.
We expect the United States specialty generics market to exhibit a CAGR of around 10% during 2021-2026.
The increasing prevalence of various life-threatening diseases, such as cancer, multiple sclerosis, hepatitis, HIV, etc., is one of the factors driving the United States specialty generics market.
With the outbreak of the COVID-19 in the United States, there is a significant rise in the R&D activities pertaining to specialty generic drugs for combating the spread of coronavirus infection.
Based on the route of administration, the United States specialty generics market can be segmented into injectables, oral, and others. Currently, injectables hold the majority of the total market share.
Based on the therapeutic application, the United States specialty generics market has been segregated into oncology, multiple sclerosis, hepatitis, HIV, other autoimmune diseases, and others, where oncology currently represents the largest segment.
Based on the distribution channel, the United States specialty generics market can be categorized into retail pharmacies, specialty pharmacies, and hospital pharmacies. Currently, retail pharmacies exhibit a clear dominance in the market.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at